NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 10.54 against a street estimate of 7.77 — a beat of 35.6%.
| Document | Date |
|---|---|
| Quarterly results · Q1 FY27 ASTRAZENECA PHARMA INDIA LIMITED – COMPANY DOCUMENT SUMMARY HEADLINE NUMBERS • Total Revenue from Operations (Q1 FY2026-27): INR 6,828 Million, repr | 2026-08-10 |
| Annual report FY2026 ASTRAZENECA PHARMA INDIA LIMITED - ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • Total revenue from operations: ₹22,756 million in FY 2025-26, | 2026-07-18 |
| Quarterly results · Q4 FY26 ASTRAZENECA PHARMA INDIA LIMITED – BOARD MEETING OUTCOME, MAY 26, 2026 --- HEADLINE NUMBERS • Total Revenue FY 2025-26: INR 22,755.8 Million – repr | 2026-05-26 |
| Quarterly results · Q2 FY26 ASTRAZENECA PHARMA INDIA LIMITED – Q2 FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 FY2026 Revenue from Operations: Rs 5,590.0 million (vs Rs 4,080 | 2025-11-07 |
| Quarterly results · Q1 FY26 ASTRAZENECA PHARMA INDIA LIMITED - Q1 FY2026 SUMMARY HEADLINE NUMBERS • Revenue from operations (Q1 FY2026): Rs 5,263.1 million, up 9.6% from Rs 4,8 | 2025-09-10 |
| Annual report FY2025 ASTRAZENECA PHARMA INDIA LIMITED – ANNUAL REPORT FY 2024-25 SUMMARY --- HEADLINE NUMBERS • Revenue from operations: ₹1,716 crore (USD 200 million m | 2025-07-22 |
| Quarterly results | 2025-02-11 |
| Quarterly results | 2024-11-13 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹36 / share ex-date Jul 31, 2026 | 2026-07-31 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AstraZeneca Pharma India Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.